Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-64041809 + Apalutamide in mCRPC
NCT02906605Phase 2Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2016
- Primary completion
- Sep 2018
- Modality
- Therapeutic Vaccines, Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of opolimogene capmilisbac in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Time to Prostate-specific Antigen (PSA) Progression at 2 years. Planned start Oct 2016; status: withdrawn.
02
Drugs
opolimogene capmilisbac
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02906605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02906605.